Prothena公共 PRTA 深 滬
已收盤 10-10 16:00:00 美东时间
10.05
-0.250
-2.43%
華盛通- 最 高10.45
- 今 開10.34
- 成交量 73.41万股
- 最 低 9.98
- 昨 收 10.30
- 總市值 5.41亿
- 52周最高 18.88
- 市盈率 靜 --
- 換手率 1.36%
- 52周最低 4.32
- 委 比 -72.26%
- 總股本 5383.00万
- 歷史最高 79.749
- 量 比 1.00
- 振 幅 4.56%
- 歷史最低 4.32
- 每 手 1
- 風險率 3.92%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高300美元，AMD获多家大行上调目标价！
今日重点评级关注：Maxim Group：维持Gain Therapeutics"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Icecure Medical"买入"评级，目标价从2美元升至2.5美元
10-08 09:14
Deep Dive Into Prothena Corp Stock: Analyst Perspectives (7 Ratings)
Throughout the last three months, 7 analysts have evaluated Prothena Corp (NASD...
10-08 05:01
Prothena's Partner Bristol Myers Squibb Receives Fast Track Designation From The FDA For BMS-986446 For The Treatment of Alzheimer's Disease
Prothena Corporation plc (NASDAQ:PRTA), announced today that Bristol Myers Squibb communicated in a press release that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a
10-02 05:12
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics granted 6,200 stock options and 3,100 RSUs to a new employee on October 1, 2025, under the Inducement Plan. The options have an exercise price of $4.41 per share, vesting over four years, while the RSUs vest over three years. These awards are contingent on continued employment. Protara is advancing transformative therapies for cancer and rare diseases, with its lead candidate, TARA-002, in Phase 2 trials for non-muscle invasi...
10-01 20:03
FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy
The FDA now requires earlier MRI screening for Alzheimer's drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients.
08-29 22:09
Piper Sandler Maintains Overweight on Prothena Corp, Lowers Price Target to $15
Piper Sandler analyst Yasmeen Rahimi maintains Prothena Corp (NASDAQ:PRTA) with a Overweight and lowers the price target from $81 to $15.
08-28 22:27
Prothena Reports Phase 1 Results For PRX012 In Alzheimer's; Explores Partnerships To Advance PRX012 And TfR-Linked Preclinical Program
As previously communicated, Prothena plans to explore potential partnership interest to advance PRX012 and its preclinical PRX012-TfR (transferrin receptor) antibodyPhase 1 ASCENT clinical program established
08-28 04:15
Chardan Capital Maintains Buy on Prothena Corp, Maintains $18 Price Target
Chardan Capital analyst Rudy Li maintains Prothena Corp (NASDAQ:PRTA) with a Buy and maintains $18 price target.
08-05 18:21
Earnings Scheduled For August 4, 2025
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is likely to rep...
08-04 16:32
A Glimpse of Prothena Corp's Earnings Potential
Prothena Corp (NASDAQ:PRTA) will release its quarterly earnings report on Monda...
08-02 05:05
